We Cure Viral Diseases with Non-Pathogenic Viruses! Leadership Team HepC is led by a seasoned executive team, with proven expertise in corporate management, business operations, drug discovery and drug development. HepC intends to keep its management and workforce streamlined and efficient. Its team of highly capable and proven business and scientific management personnel is planned to be broadened by adding operational personnel only in essential functions in the near term. Tam�s Bak�cs, MBA, Chief Executive Officer Mr. Bakacs has over 10 years of international investment management and financial services experience.�He is a well experienced global resource investment manager who was most recently�the Managing Director, founder and portfolio manager of the�Re�lsziszt�ma Marco Polo Global Equity Fund, based in Budapest, Hungary, a global commodity focused mutual fund. Previously, Mr. Bakacs worked as an investment manager at Baillie Gifford & Co. in Edinburgh, UK., and as a senior analyst at Compass Asset Management JSC in Almaty, Kazakhstan, an emerging markets based hedge fund, focusing on commodity linked equity investments.�Mr. Bakacs holds a B.S. in Accounting, Summa Cum Laude, from St. Francis College in New York and an MBA with a concentration in Finance from the UCLA Anderson School of Management. In addition, Mr. Bakacs is also a member of the Advisory Board of Alliance Mining Corp. (TSX: ALM) based in Vancouver, Canada. Tibor Bak�cs, MD, PhD, DSc, Chief Scientific Officer Dr.�Bakacs has over 30 years of experience in scientific research. His present main interests are (i) the theoretical immune models challenging conventional theories and (ii) the development of viral superinfection treatment of chronic HBV and HCV hepatitis patients. Formerly, he was the Head of Immunology at the Hungarian National Institute of Oncology. He also worked on various projects including regulation of natural killer cells and bispecific monoclonal antibodies in the mouse mammary tumor virus model. Dr.�Bakacs was visiting scientist at the Karolinska Institute in Stockholm, Christie Hospital in Manchester and at the National Cancer Institute in the USA. Currently, he is a consultant to the Department of Probability, Alfred R�nyi Institute of Mathematics. Dr.�Bakacs authored 70 scientific articles and he suggested first in the journal Vaccine and then in Lancet Inf. Dis. to examine the value of the non-pathogenic bursal disease virus superinfection treatment of decompensated viral hepatitis patients. Imre Kovesdi, PhD, Chief Operating Officer Dr.�Kovesdi has over 25 years of experience in the development of therapeutic drugs in both large pharmaceutical and biotechnology environments. He served as Chief Scientific Officer for 10 years at GenVec Inc. (NASDAQ:GNVC). He was responsible for the integration of key scientific advances and business objectives. Prior to joining GenVec, he led infectious disease projects at the Medical Research Division of the New York-based American Cyanamid Company for six years. As President of KILA Consulting LLC., he established several business collaborations between biotechnology companies and institutions. Dr.�Kovesdi is creative strategist able to see the broader scientific and business needs and break them down to specific programs and projects, and direct them to completion. He is versatile facilitator, skilled at developing preclinical, clinical and licensing partnerships, able to identify foundation solutions to major health issues. He holds a Ph.D. in molecular biology and a degree in electrical engineering. He is the holder of over 100 US and foreign patents and has authored over 130 scientific articles. Dr.�Kovesdi serves on the boards of a number of biotechnology and information technology companies.